Vivoryon Therapeutics to Report Q3 2026 Financial Results on November 5
News related to:Vivoryon Therapeutics N.V · 2 min read
Vivoryon Therapeutics N.V., a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, will release its third quarter 2026 financial results on November 5, 2026. The company, headquartered in Halle (Saale) and Munich, Germany, announced the details in a press release on October 30, 2026.
According to the release, Vivoryon will provide a business update as part of its financial results, including an updated cash runway guidance. The company's key strategic priority remains securing the necessary funding to advance varoglutamstat into a Phase 2b clinical study in patients with advanced diabetic kidney disease. Varoglutamstat, a proprietary, first-in-class orally available QPCT/L inhibitor, is being evaluated to treat diabetic kidney disease. The company has made further progress in its strategic partnering efforts and is engaged in advanced negotiations with different parties towards securing a partnership for varoglutamstat in kidney disease. In parallel, Vivoryon has implemented additional cost-saving measures aimed at preserving its financial resources while pursuing its strategic partnering activities.
The release notes that all ongoing negotiations and potential investments remain subject to the customary risks and uncertainties associated with such processes, and there can be no assurance that any transaction or investment will materialize. Vivoryon's focus on advancing its most advanced program, varoglutamstat, underscores its commitment to improving patient outcomes by changing the course of severe diseases through modulating the activity and stability of pathologically relevant proteins.
Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines for the treatment of inflammatory and fibrotic disorders of the kidney. Driven by its passion for ground-breaking science and innovation, the Company strives to improve patient outcomes by changing the course of severe diseases through modulating the activity and stability of pathologically relevant proteins. Vivoryon’s most advanced program, varoglutamstat, a proprietary, first-in-class orally available QPCT/L inhibitor, is being evaluated to treat diabetic kidney disease.
The company's strategic priority is to secure the funding necessary to advance varoglutamstat into a Phase 2b clinical study in patients with advanced diabetic kidney disease, with the aim of confirming the compelling data observed in the VIVIAD and VIVA-MIND studies. As part of its financial results, Vivoryon will provide a business update, including an updated cash runway guidance. The company has made progress in its strategic partnering efforts, engaging in advanced negotiations with different parties towards securing a partnership for varoglutamstat in kidney disease. In parallel, Vivoryon has implemented additional cost-saving measures aimed at preserving its financial resources while pursuing its strategic partnering activities.
The release concludes by noting that all ongoing negotiations and potential investments remain subject to the customary risks and uncertainties associated with such processes, and there can be no assurance that any transaction or investment will materialize.